Harness their
natural strength1,2

Consider ECP to modulate their
dysregulated immune system and support
them beyond just symptom control*3-6

*THERAKOS ECP Immunomodulation™ employs the patient's own immune cells to modulate disregulated immune function1-5,7-10.

The exact mechanism of action (MOA) of the photosensitising agent is unknown. Individual results may vary.

What do you get when you choose THERAKOS ECP Immunomodulation™?

ECP Strength

  • Evidence-based Treatment11-19
  • Immunomodulation3-5
  • Cost-effectiveness21-24


  • CELLEX™ System Performance25,26
  • Validated Technology11,26,27
  • Patient & Customer Focus
  • Access & Delivery Support
  • The Therakos Institute
Therakos Ecp Immunomodulation

Therakos ECP Immunomodulation™

Find out more about our therapy and its clinical applications

Discover More


THERAKOS™ CELLEX™ Photopheresis System

Learn about the world’s only fully integrated and validated ECP system

Discover More

Research Opportunities Educational Grants

Research Opportunities & Educational Grants

Discover educational grants and research opportunities available to you


Health Economics

Health Economics

Learn about the potential economic benefits of choosing CELLEXTM, and find out about our funding support services


Customer Support

Customer Support

Get in touch with us


Operator’s Manual. THERAKOSTM CELLEXTM Photopheresis System. Therakos. 2019. 2. Hart JW, et al. Ther Adv Hematol. 2013;4:320-334. 3. Wang L, et al. Front Immunol. 2018;9:2207. 4. Ni M, et al. Front Immunol. 2019;10:547. 5. Mankarious M, et al. Front Immunol. 2020;11:81. 6. Dignan FL, et al. Bone Marrow Transplant. 2014;49(5):704-708. 7. Yoo EK, et al. J Invest Dermatol. 1996;107:235-242. 8. Morelli AE, et al. Blood. 2003;101:611-620. 9. Craciun LI, et al. Transplantation. 2002;74:995-1000. 10. Lamioni A, et al. Transplantation. 2005;79:846-850. 11. Knobler R, et al. J Eur Acad Dermatol Venereol. 2020;34(12):2693-2716. 12. Cho A, et al. Front Med (Lausanne). 2018;5:236. 13. Trautinger F, et al. Eur J Cancer. 2017;77:57-74. 14. Padmanabhan A, et al. J Clin Apher. 2019;34(3):171- 354. 15. Alfred A, et al. Br J Haematol. 2017;177:287-310. 16. Dignan FL, et al. Br J Haematol. 2012;158(1):30–45. 17. Pierelli L, et al. Transfusion. 2013;53(10):2340-2352. 18. Zeiser R. et al. Graft-versus-Host Erkrankung, akut. 2021. Available at: Accessed February 2022. 19. Costanzo MR, et al. J Heart Lung Transplant. 2010;29(8):914-956 20. Crespo C, et al. Clin Ther. 2012;34(8):1774-1787. 21. Walczak J, et al. Value Health. 2012;15:A349. 22. de Waure C, et al. Value Health. 2015;18(4):457-466. 23. Geskin L, Malone DC. J Dermatolog Treat. 2018;29(5):522-530. 24. Mayer W, et al. Retrospective data analysis related to the use of open and closed extracorporeal photopheresis systems. Presented at the 40th annual meeting of the American Society for Apheresis; 14-18 May, 2019, Portland, USA. Available at: Accessed November 2021. 25. Linic B, et al. The implementation of ‘lean’ working practices and THERAKOSTM CELLEXTM have resulted in a 50% increase in patient treatments with the same number of nurses employed in the unit. Presented at the 20th congress of the European Hematology Association; 11-14 June, 2015, Vienna, Austria. Poster E1428. 26. Therakos (UK) Ltd. Data on file - ref-06130. 27. Therakos (UK) Ltd. Data on file - ref-04301.